NICE backs GSK’s Zejula in advanced ovarian cancer
Zejula has been recommended for use in newly diagnosed ovarian cancer patients - News - PharmaTimes
by Lucy Parsons
www.pharmatimes.com/news/nice_backs_gsks_zejlua_in_advanced_ovarian_cancer_1361315
Search results
Found 346 pages
AUTHOR: Lucy Parsons
DHSC publishes ‘UK Rare Disease Framework’
Framework identifies four key priorities and five 'underpinning themes' - News - PharmaTimes
by Lucy Parsons
www.pharmatimes.com/news/dhsc_publishes_uk_rare_disease_framework_1361056Biogen and Apple partner on cognitive health study
Study will evaluate the role of smart devices on monitoring cognitive health - News - PharmaTimes
by Lucy Parsons
www.pharmatimes.com/news/biogen_and_apple_partner_on_cognitive_health_study_1361112Scotland’s pharma sector sees increase in research investment
Industry's GVA has increased to $1.8bn according to new ABPI Scotland report - News - PharmaTimes
by Lucy Parsons
www.pharmatimes.com/news/scotlands_pharma_sector_sees_increase_in_research_investment_1361513EU approval for ViiV’s Tivicay for children living with HIV
First dispersible tablet formulation of Tivicay now available for children in the EU - News - PharmaTimes
by Lucy Parsons
www.pharmatimes.com/news/eu_approval_for_viivs_tivicay_for_children_living_with_hiv_1361245Boehringer Ingelheim announces partnership with Google
Partnership will aim to research and implement quantum computing in pharma R&D - News - PharmaTimes
by Lucy Parsons
www.pharmatimes.com/news/boehringer_ingelheim_announces_partnership_with_google_1361031Tecartus wins NICE recommendation for mantle cell lymphoma
CAR-T therapy receives NICE backing within weeks of EMA authorisation - News - PharmaTimes
by Lucy Parsons
www.pharmatimes.com/news/tecartus_wins_nice_recommendation_for_mantle_cell_lymphoma_1361514Roche’s Tecentriq/Avastin combo improves survival in liver cancer
Updated analysis is from the Phase III IMbrave150 study - News - PharmaTimes
by Lucy Parsons
www.pharmatimes.com/news/roches_tecentriqavastin_combo_improves_survival_in_liver_cancer_1361171Diurnal seeks marketing authorisation for Chronocort in the UK
MHRA submission is based on same application filed with the EMA - News - PharmaTimes
by Lucy Parsons
www.pharmatimes.com/news/diurnal_seeks_marketing_authorisation_for_chronocort_in_the_uk_1361170US breakthrough designation for ligelizumab in chronic spontaneous…
In a Phase IIb trial, more patients experienced complete resolution of hives with ligelizumab compared to Xolair - News - PharmaTimes
by Lucy Parsons
www.pharmatimes.com/news/us_breakthrough_designation_for_ligelizumab_in_chronic_spontaneous_urticaria_1361362
